E. Lawrence J. Dreskin Flanagan

141 TUESDAY SCIENTIFIC SESSIONS Final Program A-1280 Tigecycline and Enterobacter Invasive Infections: PKPD Parameters Using Monte Carlo Simulation J. Lepe 1 , C. Martín-Gandul 1 , J. Rodríguez-Martínez 2 , O. Gasch 3 , C. Ruiz de Alegría 4 , R. Lara 5 , C. Fernández-Mazarrasa 4 , F. Tubau 3 , F. Rodríguez-López 5 , L. Martínez-Martínez 4 , M. Jiménez-Mejías 1 ; 1 Univ. Hosp. Virgen del Rocío, Sevilla, Spain, 2 Univ. Hosp. Virgen Macarena, Sevilla, Spain, 3 Univ. Hosp. Bellvitge, Barcelona, Spain, 4 Univ. Hosp. Marqués de Valdecillas, Santander, Spain, 5 Univ. Hosp. Reina Sofía, Córdoba, Spain. A-1281 Pharmacokinetics of [14c]-Labeled Omadacycline PTK 0796 in Healthy Male Subjects H. Sun 1 , L. Ting 1 , J. Flarakos 1 , K. Dole 1 , J. Praestgaard 1 , S. J. Kovacs 1 , D. S. Stein 1 , G. Sunkara 1 , S. K. Tanaka 2 ; 1 Novartis, East Hanover, NJ, 2 Paratek Pharmaceuticals, Boston, MA. A-1282 Pharmacokinetics of Omadacycline PTK 0796 in Subjects with Hepatic Impairment L. Ting 1 , S. J. Kovacs 1 , J. Praestgaard 1 , R. Maietta 2 , D. S. Stein 1 , G. Sunkara 1 ,

M. P. Draper

3 , H. Sun 1 ; 1 NIBR, Novartis Pharmaceuticals, East Hanover, NJ, 2 NIBR, Novartis Pharmaceuticals, Cambridge, MA, 3 Paratek Pharama- ceuticals, Boston, MA. A-1283 Pharmacokinetics and Safety of Morinidazole in Patients with Moderate Impaired Hepatic Function Compared with Healthy Volunteers X. Wu, Z. Chen, J. Wu, G. Cao, J. Yu, Bachelor, Y. Shi, Y. Zhang, J. Zhang; Inst. of Antibiotics, Huashan Hosp., Fudan Univ., Shanghai, China. A-1284 Metabolism and Excretion of PMX-30063: A Novel Class of Antibiotics

B. Korczak, D. Liu, R. Scott; Polymedix, Radnor, PA. A-1285

Urinary Antibacterial Activity of BAL30072 against Uro- pathogens After IV Administration F. M. E. Wagenlehner 1 , B. Blenk 2 , C. Wagenlehner 1 , H. Blenk 2 , K. G. Naber 3 ; 1 Justus Liebig Univ., Giessen, Germany, 2 Eukarion Inst., Nuernberg, Germany, 3 Tech. Univ., Munich, Germany. A-1286 Systemic Safety Profile of Solithromycin in Phase 1 2 Clinical Trials

D. Oldach, B. Jamieson, K. Clark, K. Keedy, P. Fernandes; Cempra, Inc., Chapel Hill, NC.

------------------------------------------------------------------------ 163A Poster Session PharmacokineticsPharmacodynamics of New and Old Oxazolidinones Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: A-1287 Pharmacokinetics PK of Intravenous IV Linezolid LZD in Moderately to Morbidly Obese Adults A. A. Bhalodi, P. K. Papasavas, D. S. Tishler, D. P. Nicolau, J. L. Kuti; Ctr. for Anti-Infect. Res. Dev., Hartford Hosp., Hartford, CT. A-1288 Clinical PharmacokineticPharmacodynamic Profile of Linezolid in Multidrug Resistant Gram Positive Infections

H. Mikamo, Y. Yamagishi; Aichi Med. Univ., Aichi, Japan. A-1289

Radezolid Demonstrates Favorable Safety Compared to Linezolid in a Three-Month Rat Toxicology Study C. Moore 1 , H. Dedhia 1 , E. Duffy 2 , J. Longcor 2 , E. Burak 2 , E. Bortolon 2 , D. Molstad 2 , Y. Wu 2 , H. Jing 2 , D. Li 2 , R. Hanselmann 2 , M. Reeve 2 , A. Marra 2 ; 1 Covance Lab., Chandler, AZ, 2 Rib-X Pharmaceuticals, New Haven, CT. A-1290 A Phase 1, Single and Multiple Ascending Intravenous IV Dose Study of Safety, and Pharmacokinetics PK of Radezolid RDZ in Healthy Subjects

L. E. Lawrence

1 , A. Marra 1 , J. Longcor 1 , R. Hoover 1 , M. Benedict 2 , C. Smith 2 , Y. Cai 2 , M. Medlock 2 ; 1 Rib-X Pharmaceuticals Inc., New Haven, CT, 2 PPD, Wilmington, NC. A-1291 Study of the Cellular Uptake and Subcellular Distribution of the Oxazolidinone Tedizolid TZD in Murine J774 Macro- phages: Lack of Association with Mitochondria D. Das, A. Lambert, G. Muccioli, P. M. Tulkens, F. Van Bambeke; Univ. Catholique de Louvain, Bruxelles, Belgium. A-1292 Safety and Pharmacokinetics after Single Oral and IV Ad- ministration of Tedizolid Phosphate in Adolescent Patients K. A. Muñoz 1 , H. Dreskin 1 , J. Bradley 2 , A. Arrieta 3 , E. Capparelli 2 , R. Jacobs 4 , S. L. Minassian 1 , E. Fang 1 , P. Prokocimer 1 , S. Flanagan 1 ; 1 Trius Therapeutics, Inc., San Diego, CA, 2 UCSD, San Diego, CA, 3 CHOC, Orange, CA, 4 ACH, Little Rock, AR. A-1293 Safety and Pharmacokinetics of Single Oral Administration of Tedizolid Phosphate in Healthy Elderly Subjects and Adult Control Subjects

H. J. Dreskin

1 , K. Muñoz 1 , E. Fang. 1 , S. L. Minassian 1 , D. Subich 2 , S. Fla- nagan 1 , P. Prokocimer 1 ; 1 Trius Therapeutics, Inc., San Diego, CA, 2 Covance, Inc., Orlando, FL. A-1294 A Phase 1 Study of Intravenously Administered Tedizolid Phosphate in Subjects with Advanced Renal Impairment

S. Flanagan

1 , D. Morris 2 , T. Boyea 1 , H. Dreskin 1 , S. L. Minassian 1 , H. Alcorn, Jr 3 , T. Marbury 4 , M. Abdelhameed 2 , E. Fang 1 , P. Prokocimer 1 ; 1 Trius, San Diego, CA, 2 Covance, Madison, WI, 3 DaVita, Minneapolis, MN, 4 Orlando Clinical Res. Ctr., Orlando, FL. A-1295 A Phase 1 Study of Orally Administered Tedizolid Phosphate in Subjects with Moderate or Severe Hepatic Impairment T. Boyea 1 , H. Dreskin 1 , S. L. Minassian 1 , T. C. Marbury 2 , H. J. Alcorn, Jr 3 , E. Fang 1 , P. Prokocimer 1 , S. Flanagan 1 ; 1 Trius Therapeutics, San Diego, CA, 2 Orlando Clinical Res. Ctr., Orlando, FL, 3 DaVita Clinical Res., Minneapo- lis, MN. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 164 B Poster Session Antimicrobial Therapy in Animal Models II Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: B-1296 Insights into the Activity of Pyrazinamide in Immune-Com- petent and Immune-Deficient Murine Models of Tuberculosis

D. V. Almeida